Business
Predicting immunotherapy response in SCLC
Predicting immunotherapy response in SCLC.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n \n \n 16 June 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n \n PARSORTIX SYSTEM DEMONSTRATES\n \n \n POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER\n \n \n \n \n \n \n \n \n \n CTCs isolated by the Parsortix system can be used to evaluate PD-L1 expression\n \n \n \n \n \n \n \n \n \n Marker independent isolation of CTCs enables isolation of both EpCAM-negative and positive CTCs from small cell lung cancer patients\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,\n is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in small cell lung cancer (SCLC) patients using the Parsortix® system. The primary aim of this study was to demonstrate the ability to evaluate the PD-L1 status of isolated circulating tumour cells (CTCs), providing an alternative sample than solid tissue in SCLC, which may help to predict response to immunotherapy.\n \n \n \n \n \n The Parsortix system was selected by researchers for the study due to its ability for unbiased CTC enrichment enabling the isolation of both EpCAM-positive and EpCAM-negative cancer cells.\n This is clinically relevant because, although there is an abundance of high EpCAM expressing CTCs in the SCLC population, EpCAM expression can be lost or downregulated during cancer progression. This progression is associated with increased metastatic potential and worse prognosis, but still many CTC isolation methods, including the leading antibody-based system, only isolate and identify cells expressing the EpCAM marker.\n \n \n \n \n \n Blood collected from 18 SCLC patients was processed using the Parsortix system (20 samples; 18 samples collected prior to treatment for all patients, with two patients also providing samples at relapse). CTCs were identified in 50% of the samples, from ten of the 18 SCLC patients. The researchers found EpCAM-negative CTCs in three patients, with a small proportion of the CTCs identified also positive for PD-L1 expression. Of the ten CTC-positive patient samples, four samples (40%) had PD-L1-positive CTCs.\n \n \n \n \n \n This study demonstrates both the ability of the Parsortix syste...